Medical News

RSS

AHRQ selects Outcome Sciences to study effects of different treatments for open angle glaucoma

Outcome Sciences, Inc. (OUTCOME), the leading provider of patient registries, studies, and technologies for evaluating real-world outcomes, today announced that the Agency for Healthcare Research and Quality (AHRQ) has selected Outcome as the DEcIDE Center for a study designed to compare the effectiveness of medications versus surgery for the treatment of open-angle glaucoma. The study will enroll 2,600 patients from 30 sites across the United States and is intended to provide new scientific information about the effects of different treatment approaches in individuals who have glaucoma.

13 Aug 2010

Mercator signs license agreement with MD Anderson Cancer Center and closes $2.0 million seed round

Mercator Therapeutics, the first biopharmaceutical company to use in vivo phage display technology systematically to develop novel cancer drugs, today announced the signing of a license agreement with The University of Texas MD Anderson Cancer Center and the closing of a $2.0 million seed round.

13 Aug 2010

New multidisciplinary approach to glioblastoma multiforme treatment offers extended survival rates

The Hospital Universitario Donostia (at the city of Donostia-San Sebasti-n in the Basque province of Gipuzkoa) has incorporated a new glioblastoma multiforme treatment protocol, which could be the starting point for a more effective treatment of this type of cancer. Doctor Nicol-s Sampr-n, specialist in Neurosurgery at the hospital, has presented his PhD at the University of the Basque Country (UPV/EHU) based on the first results of the new treatment method. The work is entitled Glioblastoma multiforme. Analysis of survival and prognostic factors.

13 Aug 2010

American CareSource second-quarter revenues decrease to $16.0 million

American CareSource Holdings Inc. today announced second quarter 2010 revenues of $16.0 million compared to $17.1 million in the corresponding prior year quarter. Net income for the second quarter 2010 was $299,000, or $0.02 per diluted share, compared to $534,000, or $0.01 per diluted share, in the corresponding prior year quarter. Net income for the second quarter 2010 included a federal income tax provision of $137,000, or $0.01 per diluted share, which was not included in net income for the second quarter 2009.

13 Aug 2010

Humanetics Corporation secures license to provide treatment for ionizing radiation exposure

In a move likely to secure its place as a leading provider of medical radiation countermeasures, Humanetics Corporation today announced that it has secured exclusive worldwide licenses to two new treatments that provide short and long-term post-exposure protection from ionizing radiation acquired during a terrorist act, nuclear or radiological attack or accident, as part of cancer radiotherapy or even during routine diagnostic CT scans.

13 Aug 2010

Companies reorganizing under Chapter 11 battle with former employees over lifetime health benefits

The Wall Street Journal: "Linda Roberts thought she would enjoy lifetime health benefits after a dozen years lifting radiators and iron in a factory for Visteon Corp. But the car-parts maker won bankruptcy-court approval to terminate those retiree benefits, just months after Ms. Roberts, 62 years old, was diagnosed with multiple myeloma and leukemia.

13 Aug 2010

NIEHS procures Provantis preclinical software solution for National Toxicology Program studies

Instem, a leading provider of early drug development software solutions, announced today that the National Institute of Environmental Health Sciences has purchased the Provantis® preclinical software solution to support the collection, management and maintenance of the reproductive, perinatal and developmental National Toxicology Program studies. These studies are done predominantly at contractor laboratories at various sites throughout the United States.

13 Aug 2010

New implantable device to prevent sudden cardiac arrest

Northwestern Memorial Hospital heart rhythm specialists recently gave a 34-year-old man a makeshift paramedic—who's always on duty—inside of his chest by implanting a device that did not require X-ray assistance and the usual snaking of wires leading to the heart. In fact, the innovative device rests just beneath the surface of the skin and its components are positioned using the patient's own anatomical landmarks.

13 Aug 2010

Neurologix second-quarter net loss increases to $4.5 million

Neurologix, Inc., a biotechnology company developing innovative gene therapies for the brain and central nervous system, today reported its financial results for the three and six months ended June 30, 2010.

13 Aug 2010

European Association of Urology to publish first case series on RALP

In European Urology, the official journal of the European Association of Urology, a new section will be published as of the September issue: Case Series of the month. This series is dedicated to publishing promising studies which have so far only preliminary results. The Case Series reports on no more than 10 patients and includes illustrative images. A Continuing Medical Education question with multiple choice answers is also included to enable readers to earn CME points.

13 Aug 2010

Epitomics spins-out Apexigen to develop and commercialize humanized rabbit monoclonal antibodies

Epitomics, Inc. today announced that it has spun-out to its shareholders a new biotechnology company called Apexigen, Inc., which will focus on the development and commercialization of humanized monoclonal antibodies for treatment of cancer and immuno-disorders.

13 Aug 2010

Researchers develop new implantable metamaterials to destroy cancerous tissue

The research, reported online July 21, 2010, in the journal Advanced Materials, provides a promising path towards the development of a new class of metamaterial-inspired implantable biosensors and biodetectors.Metamaterials are artificial electromagnetic composites, typically made of highly conducting metals, whose structures respond to electromagnetic waves in ways that atoms in natural materials do not. The most futuristic metamaterials would absorb all light, to create heat to destroy cancerous tissue, or bend light completely around an object, rendering that object invisible-an imaginary delight for fans of science fiction or spy novels.

13 Aug 2010

A*STAR's Singapore Immunology Network, Institut M-rieux and bioM-rieux partner in TB research

An investment of S$3 million is being pumped into tuberculosis (TB) research by A*STAR's Singapore Immunology Network (SIgN), bioindustrial group Institut M-rieux and its in vitro diagnostics company bioM-rieux. The project, which involves setting up a joint laboratory in Biopolis, Singapore aims to investigate and identify novel biomarkers that could allow early identification of individuals at risk of TB disease development and disease reactivation. This could lead to better diagnosis and treatment for the highly contagious disease.

13 Aug 2010

Kibow to support KDAE week for educating policymakers about kidney disease

Kibow Biotech would like to show its support for Kidney Disease Awareness and Education (KDAE) Week 2010, organized by American Nephrology Nurses' Association (ANNA). Kidney Disease Awareness and Education Week is a week dedicated to educating policymakers and their staff members about the needs of patients suffering from or at risk for end stage renal disease (ESRD).

13 Aug 2010

NovaBay second-quarter net loss increases to $1.2 million

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported second quarter financial results and highlighted the clinical progress of its in-house programs.

13 Aug 2010

Gore announces first implantation in IDE clinical study of ACUSEAL Vascular Graft in hemodialysis patients

W. L. Gore & Associates reported that the first patient, in an Investigational Device Exemption (IDE) clinical study evaluating the self sealing GORE® ACUSEAL Vascular Graft in patients on hemodialysis, has been surgically implanted with the device. The successful surgical procedure was performed on July 29, 2010 at Greenville Hospital System in Greenville, South Carolina. Less than 24 hours after the device was implanted it was successfully cannulated or punctured for initial hemodialysis access.

13 Aug 2010

NAC to deliver education program on asthma management for youth

As children with asthma head back to school this fall, the National Asthma Campaign Foundation (NAC) is partnering with Respiratory Health Association of Metropolitan Chicago (RHAMC) to deliver Fight Asthma Now (FAN), an asthma education program that teaches youth to control and manage their asthma.

13 Aug 2010

Guided Therapeutics second-quarter service revenue increases to $0.8 million

Guided Therapeutics, Inc. today announced its operating results for the second quarter and first six months of 2010.

13 Aug 2010

CLC bio, PSSC Labs announce new turnkey solution for full-genome assembly and analysis

Today, CLC bio and PSSC Labs announced a new turnkey solution, CLC Genomics Factory, for assembly, read mapping, and subsequent downstream analysis of very large amounts of high-throughput DNA and RNA sequencing data. Built as a high-performance bioinformatics appliance, CLC Genomics Factory comes in three different sizes with varying numbers of compute nodes, capable of processing the data output from up to 10 Illumina HiSeq2000 or 7 Life Technologies SOLiD 4 systems.

13 Aug 2010

Aeolus completes $1.0M financing to initiate human clinical studies of AEOL 10150 for cancer

Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.0 million financing with two existing institutional shareholders, both of which are affiliates of Xmark Opportunity Partners, LLC.

13 Aug 2010

Medical News

AHRQ selects Outcome Sciences to study effects of different treatments for open angle glaucoma

Mercator signs license agreement with MD Anderson Cancer Center and closes $2.0 million seed round

New multidisciplinary approach to glioblastoma multiforme treatment offers extended survival rates

American CareSource second-quarter revenues decrease to $16.0 million

Humanetics Corporation secures license to provide treatment for ionizing radiation exposure

Companies reorganizing under Chapter 11 battle with former employees over lifetime health benefits

NIEHS procures Provantis preclinical software solution for National Toxicology Program studies

New implantable device to prevent sudden cardiac arrest

Neurologix second-quarter net loss increases to $4.5 million

European Association of Urology to publish first case series on RALP

Epitomics spins-out Apexigen to develop and commercialize humanized rabbit monoclonal antibodies

Researchers develop new implantable metamaterials to destroy cancerous tissue

A*STAR's Singapore Immunology Network, Institut M-rieux and bioM-rieux partner in TB research

Kibow to support KDAE week for educating policymakers about kidney disease

NovaBay second-quarter net loss increases to $1.2 million

Gore announces first implantation in IDE clinical study of ACUSEAL Vascular Graft in hemodialysis patients

NAC to deliver education program on asthma management for youth

Guided Therapeutics second-quarter service revenue increases to $0.8 million

CLC bio, PSSC Labs announce new turnkey solution for full-genome assembly and analysis

Aeolus completes $1.0M financing to initiate human clinical studies of AEOL 10150 for cancer

Dr. Anthony Grice

Building quality into drug development for safer, faster medicines

Advancing Human Muscle Models for Drug Development and Preclinical Testing

Latest News